Payload Information

General Information of This Payload
Payload ID
PAY0ATCSD
Name
Maytansinoid derivative
Synonyms
Maytansinoid derivative
   Click to Show/Hide
Target(s) Microtubule (MT)
 Target Info 
Structure
Formula
C38H53ClN4O11
Isosmiles
CNC(=O)CCCC(=O)N(C)C(C)C(=O)OC1CC(=O)N(C)c2cc(cc(OC)c2Cl)C/C(C)=C\C=C\C(OC)C2(O)CC(OC(=O)N2)C(C)C2OC12C
InChI
InChI=1S/C38H53ClN4O11/c1-21-12-10-13-28(51-9)38(49)20-27(52-36(48)41-38)22(2)34-37(4,54-34)29(53-35(47)23(3)42(6)31(45)15-11-14-30(44)40-5)19-32(46)43(7)25-17-24(16-21)18-26(50-8)33(25)39/h10,12-13,17-18,22-23,27-29,34,49H,11,14-16,19-20H2,1-9H3,(H,40,44)(H,41,48)/b13-10-,21-12-
InChIKey
QTQHPYCMLRPHLI-USJWDNIUSA-N
Pharmaceutical Properties
Molecule Weight
777.312
Polar area
185.57
Complexity
54
xlogp Value
3.4308
Heavy Count
54
Rot Bonds
9
Hbond acc
11
Hbond Donor
3
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Pertuzumab zuvotolimod [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
7.10%
Patients Enrolled
Patients have HER2-expressing or amplified solid tumors.
Administration Dosage
0.60 mg/kg administered Q2 weeks.
Related Clinical Trial
NCT Number NCT04460456  Phase Status Phase 1
Clinical Description
A phase 1/1b, open-label, dose escalation and expansion study of SBT6050 alone and in combination with PD-1 inhibitors in subjects with advanced solid tumors expressing HER2.
Experiment 2 Reporting the Activity Date of This ADC [5]
Related Clinical Trial
NCT Number NCT05091528  Phase Status Phase 1
Clinical Description
An open-label, phase 1/2, dose-escalation and expansion study of SBT6050 combined with other HER2-directed therapies in subjects with pretreated unresectable locally advanced and/or metastatic HER2-expressing or HER2-amplified cancers.
BAT-8001 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Objective Response Rate (ORR)
41.40%
Patients Enrolled
HER2-positive locally advanced or metastatic breast cancer.
Administration Dosage
Patients received BAT8001 intravenously in a 21-day cycle, with dose escalation in 5 cohorts: 1.20, 2.40, 3.60, 4.80, and 6.00 mg/kg.
Related Clinical Trial
NCT Number NCT04189211  Phase Status Phase 1
Clinical Description
An open-label, dose escalation phase 1 clinical trial on safety, tolerability and pharmacokinetics of BAT8001 for injection in patients with HER2-positive solid tumors.
Primary Endpoint
For BAT8001, 3.60 mg/kg was determined to be the MTD.
Experiment 2 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT04185649  Phase Status Phase 3
Clinical Description
A clinical study evaluating the efficacy and safety of BAT8001 injection for the treatment of HER2-positive advanced breast cancer - a multicenter, randomized, open-label, positive-controlled, superiority phase 3 clinical trial in china.
Experiment 3 Reporting the Activity Date of This ADC [4]
Related Clinical Trial
NCT Number NCT04151329  Phase Status Phase 1/2
Clinical Description
Evaluation for the safety of BAT1306 and BAT8001 injection for the treatment of patients with HER2-positive advanced solid tumors phase 1/2a clinical trials of sexual, tolerability and pharmacokinetic characteristics.
Experiment 4 Reporting the Activity Date of This ADC [6]
Related Clinical Trial
NCT Number NCT04189211  Phase Status Phase 1
Clinical Description
An open-label, dose escalation phase 1 clinical trial on safety, tolerability and pharmacokinetics of BAT8001 for injection in patients with HER2-positive solid tumors.
BAT-8003 [Terminated in phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [7]
Related Clinical Trial
NCT Number NCT03884517  Phase Status Phase 1
Clinical Description
An open, escalating phase 1 clinical trial of BAT8003 (for injection) on the safety, tolerability and pharmacokinetics for patients with advanced epithelial cancer.
References
Ref 1 A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results. 2020 Dec 7.
Ref 2 Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer Commun (Lond). 2021 Feb;41(2):171-182.
Ref 3 A Clinical Study Evaluating the Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer - A Multicenter, Randomized, Open-label, Positive-controlled, Superiority Phase III Clinical Trial in China, NCT04185649
Ref 4 Evaluation for the Safety of BAT1306 and BAT8001 Injection for the Treatment of Patients With HER2-positive Advanced Solid Tumors Phase I/IIa Clinical Trials of Sexual, Tolerability and Pharmacokinetic Characteristics, NCT04151329
Ref 5 An Open-label, Phase 1/2, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers, NCT05091528
Ref 6 An Open-Label, Dose Escalation Phase I Clinical Trial on Safety, Tolerability and Pharmacokinetics of BAT8001 for Injection in Patients With HER2-Positive Solid Tumors, NCT04189211
Ref 7 An Open, Escalating Phase I Clinical Trial of BAT8003 (for Injection) on the Safety, Tolerability and Pharmacokinetics for Patients With Advanced Epithelial Cancer

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.